Natco Pharma Limited · NSE:NATCOPHARM
Natco Pharma — Investor Presentation (November 2016)
20 slides from Natco Pharma's investor presentation, November 2016
Slide 1: Expanding Horizons
NATCO Pharma Limited Expanding Horizons Investor Presentation November 2016 1
Slide 2: Disclaimer / Important Disclosure
Disclaimer / Important Disclosure This presentation has been prepared by Natco Pharma Limited (the “Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation should not be construed as
Slide 3: NATCO Pharma at a Glance
NATCO Pharma at a Glance Vertically integrated pharmaceutical company with focus on niche therapeutic areas and complex products in Finished Dosage Formulations (“FDF”) and Active Pharmaceutical Ingredients (“APIs”) Diversified business model with presence across segments including Domestic & In
Slide 4: Company Evolution
Company Evolution 2003: Launched Oncology division 2014: Incorporated Natco 1986: Inaugurated Parentals with introduction of flagship brand 2009: Inaugurated Natco Organics Ltd. Pharma Australia Pty Manufacturing facility at VEENAT (generic Imatinib Mesylate) at Chennai, India, with facilities Nagar
Slide 5: Key Business Segments
Key Business Segments Formulations API Others (Domestic & Exports) International Domestic Portfolio of niche and complex Leading Player1 in India’s Filed 33 DMFs in US with Operates one pharmacy store products for US generic oncology space led by over 16 products under in US (Sold on April 7
Slide 6: Expanding US Footprint Through a Differentiated Product Pipeline
Expanding US Footprint Through a Differentiated Product Pipeline of Niche and Complex Products Pipeline of niche and complex generics products in US 38 ANDA filings including 16 Para IV filings with USFDA (as on March 31, 2016) targeting a combined market of over US$16.3 bn^ 16 approved ANDAs
Slide 7: Expanding US Footprint Through a Differentiated Product Pipeline (Cont'd)
Expanding US Footprint Through a Differentiated Product Pipeline of Niche and Complex Products (Cont’d) Overview of Key Filings Therapeutic Segment / Key Brand Molecule Dosage Form Para IV Para III Market Size (US$mn)# Indication Copaxone 20&40mg Glatiramer 20&40mg Multiple Sclerosis PFS 4,349.60
Slide 8: De-risked Business Model through Partnership with Global Pharmaceutical Players
De-risked Business Model through Partnership with Global Pharmaceutical Players Mitigation Strategy Adopted and successfully implemented partnership strategy for international formulations product ─ Has product specific partnerships with global generic players at different stages of a potential AN
Slide 9: Leading Position in Domestic Oncology Segment
Leading Position in Domestic Oncology Segment Focus on oncology segment in domestic market and hold leading Oncology Revenue - Gross (INRmn) market share in operated portfolio of product 2,526 Entered the segment with launch of Veenat (Imatinib generic 1,947 version) in 2003 1,572 Progressivel
Slide 10: Leading Position In Domestic Oncology Segment (Cont'd)
Leading Position In Domestic Oncology Segment (Cont’d) Key brands listed: Supportive Care Zoldonat Glioma (Zoledronic Acid) Temonat (Temozolomide) Lymphoma Breast Cancer Bendit Fulvenat (Fulvestrant) (Bendamustine) Leukemia Xtane (Exemestane) Veenat (Imatinib) Letronat (Letrozole) Lung Cancer Geftin
Slide 11: Expanding Presence in Domestic Specialty Pharma Segment
Expanding Presence in Domestic Specialty Pharma Segment Domestic Specialty Pharma Sovaldi Opportunity Launched generic Sofosbuvir and its combinations for the treatment of Hepatitis C in India & Nepal under its brand HEPCINAT & HEPCINAT LP Portfolio of 13 products catering ─ Medicine used for ch
Slide 12: Expanding Europe & RoW Presence
Expanding Europe & RoW Presence RoW formulation growth to be driven by launches in EU, scale up in Latin America and Canada and phased launch of generic Sovaldi Europe Sell our products in Eastern Europe, UK and Germany 4 approvals Distribution arrangements with our business partner Canada R
Slide 13: Strong In-House API Development with Vertical Integration
Strong In-House API Development with Vertical Integration for Key Formulation Products Gross API Revenue (INR mn) Strategically important business – develops APIs primarily for captive consumption of its FDF portfolio as well as third party sales 2,571 2,221 Portfolio of 33 USDMFs with over 16 p
Slide 14: Strong Research & Development Capabilities
Strong Research & Development Capabilities 16 ANDAs Approved Strong R&D capabilities demonstrated by its complex and niche product filings in (including 3 tentative approvals) formulations and API segments Two well equipped research facilities with capabilities across synthetic chemistry, 16 Para
Slide 15: Commitment to Manufacturing Excellence with a Culture of Quality and Compliance
Commitment to Manufacturing Excellence with a Culture of Quality and Compliance Formulations Manufacturing Facilities Kothur Facility Nagarjuna Sagar Facility Dehradun Unit 6 Facility Dehradun Unit 7 Facility Guwahati Facility Capability: Tablets, Capsules, Capability: Ampoules, Vials, Capabil
Slide 16: Experienced Management
Experienced Management Mr. V.C Nannapaneni Holds Masters degree in Pharmaceutical Administration from the Long Island University, US Chairman and Director Over 42 years of experience in the Pharmaceutical Industry Mr. Rajeev Nannapaneni Holds bachelors degree in Quantitative Economics and Hist
Slide 17: Demonstrated Track Record of Topline and Earnings Growth
Demonstrated Track Record of Topline and Earnings Growth Total Revenue (INR mn) EBITDA (INR mn) and EBITDA Margin (%) 22.2% 22.4% 26.0% 25.4% 24.3% 2,805 11,524 2,131 1,960 8,402 1,507 7,556 6,729 1,185 5,329 FY2012 FY2013 FY2014 FY2015 FY2016 FY2012 FY2013 FY2014 FY2015 FY2016 PAT (INR mn) and PAT
Slide 18: Historical Financials
Historical Financials Consolidated Profit & Loss Statement (INR Mn) Consolidated Balance Sheet (INR Mn) Consolidated Cash Flow Statement (INR Mn) 31- 31- 31- 31-Mar- 31-Mar- 31-Mar- 31-Mar-16 31-Mar-15 31-Mar-14 Particulars Particulars Mar-16 Mar-15 Mar-14 16 15 14 Revenue from operations (gross) 11
Slide 19: Historical Financials (contd.)
Historical Financials (contd.) Segmental Breakdown (INR Mn) Consolidated Financial Results (INR Mn) Revenue Division Q2 – FY17 Q1 – FY17 Q2 - FY16 Q2 - FY17 Q1 - FY17 Q2 - FY16 API, Domestic 146.2 82.3 70.1 Total Revenues 4710.4 3454.7 2450.9 API, Exports 330.0 212.3 317.5 API Gross Revenue 476.1 29
Slide 20: Q2 – FY17 Highlights
Q2 – FY17 Highlights (July – September 2016) Received Establishment Inspection Report (EIR) in August 2016 from the U.S. Food and Drug Administration (FDA) for both its drug manufacturing facility in Kothur, India & at its Chemical Division, Chennai, India, for the inspections conducted during the